Does Ozempic Cause Cancer? What the Research Actually Shows

Does Ozempic Cause Cancer? What the Research Actually Shows

If you've been researching Ozempic or semaglutide for weight management, you've probably stumbled across the cancer warning in the fine print — and it's unsettling. The FDA requires a black box warning on every GLP-1 receptor agonist label, flagging a possible link to thyroid tumours. That warning is hard to ignore.

But does that warning mean Ozempic causes cancer in humans? The short answer: the evidence doesn't support that conclusion — but the nuances matter, and you deserve a clear explanation of what the data actually says.

What Is the FDA Black Box Warning?

A black box warning is the most serious caution the U.S. Food and Drug Administration places on a drug label. For semaglutide (the active ingredient in Ozempic and Wegovy), the warning reads:

"In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans."

Two things stand out. First, the tumours occurred in rodents — specifically rats and mice — exposed to semaglutide at doses many times higher than those used in humans, and over prolonged durations. Second, the FDA explicitly states it is unknown whether the same effect occurs in people.

Why the warning at all, then? Because medullary thyroid carcinoma (MTC) is serious enough that regulators choose caution over silence. The warning also means semaglutide is contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — conditions that already elevate MTC risk.

Why Rodent Data Doesn't Automatically Apply to Humans

The biology of thyroid C-cells differs substantially between rodents and humans. Rats have a much higher baseline density of C-cells and express GLP-1 receptors on those cells far more abundantly than humans do. When GLP-1 receptors in rat C-cells are chronically stimulated, it can trigger hyperplasia and, over time, tumour formation. Human C-cells express GLP-1 receptors at comparatively low levels — so the same biological trigger is far less potent.

Multiple regulatory agencies — including the European Medicines Agency (EMA) and Health Sciences Authority (HSA) in Singapore — reviewed these rodent studies during approval and reached the same conclusion: the animal findings are not considered predictive of MTC risk in the human population.

What the SUSTAIN Trials Tell Us

The SUSTAIN clinical trial programme is one of the most comprehensive cardiovascular safety databases ever assembled for a diabetes drug. Across SUSTAIN 1 through SUSTAIN 10, more than 10,000 patients with type 2 diabetes received semaglutide — some for up to two years.

Across these trials, researchers tracked adverse events meticulously, including malignancies. The incidence of thyroid neoplasms (including MTC) in semaglutide-treated patients was not statistically different from placebo. No signal of increased thyroid cancer emerged in the human trial population despite years of follow-up.

The SUSTAIN 6 cardiovascular outcomes trial (CVOT) — the most scrutinised of the group — specifically assessed a high-risk population with established cardiovascular disease. Even in this group, no elevated thyroid cancer signal was detected.

The SELECT Trial: 17,000 Patients, Three Years of Follow-Up

The New England Journal of Medicine published the SELECT trial results in 2023 (Lincoff et al.). This was a landmark randomised, double-blind, placebo-controlled trial involving 17,604 adults with pre-existing cardiovascular disease and a BMI ≥ 27 — importantly, without type 2 diabetes. Participants received 2.4 mg semaglutide weekly or placebo for a median follow-up of 33 months.

The primary finding was a 20% reduction in major adverse cardiovascular events (MACE). For cancer risk specifically, the rate of malignant neoplasms was similar between the semaglutide and placebo groups. This is significant: SELECT is the largest, longest semaglutide trial in people without diabetes, and it produced no cancer signal.

A 2024 analysis of SELECT data also examined site-specific cancer rates and found no statistically significant increase in any cancer type — including thyroid, colorectal, pancreatic, or breast — in the semaglutide arm.

What About Pancreatitis and Pancreatic Cancer?

This question deserves its own section because pancreatitis — inflammation of the pancreas — is a known rare adverse event with GLP-1 receptor agonists, and some researchers had hypothesised it could be a pathway to pancreatic cancer.

The FDA, EMA, and multiple independent meta-analyses have reviewed this question. The current consensus: there is no established causal link between GLP-1 receptor agonist use and pancreatic cancer. Pancreatitis risk, while real and worth monitoring, is rare and has not translated into elevated pancreatic cancer rates in human clinical data.

Semaglutide labels do carry a pancreatitis warning. If you experience persistent severe abdominal pain while on the medication, you should discontinue use and seek medical attention immediately.

Emerging Research: GLP-1s May Actually Reduce Some Cancer Risks

Here's a finding that often gets lost beneath the cancer concern headlines: several observational studies suggest GLP-1 receptor agonists may be associated with lower incidence of certain obesity-related cancers.

Obesity is a well-established risk factor for at least 13 types of cancer, including endometrial, liver, kidney, and colorectal cancers. A 2024 meta-analysis of real-world data from GLP-1-treated patients found reduced incidence of colorectal cancer compared to matched controls on other antidiabetic agents.

This doesn't mean Ozempic prevents cancer — the evidence is associational, not causal. But it does add important context: the drug's weight-reducing effects may, over time, reduce exposure to one of the most significant cancer risk factors in modern populations.

Who Should Be Extra Cautious?

Even with the reassuring clinical data, certain people should not take semaglutide:

• Personal or family history of MTC — contraindicated
• MEN 2 (Multiple Endocrine Neoplasia type 2) — contraindicated
• History of pancreatitis — discuss carefully with your doctor
• Active malignancy being treated — discuss with your oncologist first

If none of these apply to you, the cancer-related black box warning does not mean you face elevated cancer risk from semaglutide use at therapeutic doses.

Frequently Asked Questions

Q: Does Ozempic cause thyroid cancer? No human clinical trial has demonstrated that semaglutide causes thyroid cancer. The FDA black box warning is based on rodent studies; the relevance to humans is considered low due to biological differences in C-cell density and GLP-1 receptor expression.

Q: What is the SELECT trial and why does it matter? SELECT is a 17,604-patient randomised controlled trial published in 2023 that followed participants for nearly three years. It found no significant difference in cancer incidence between semaglutide and placebo groups — the most robust human evidence available.

Q: Should I be concerned about the black box warning? The warning exists because medullary thyroid carcinoma is serious and regulators choose to err on the side of caution when animal data raises a signal. However, if you don't have a personal or family history of MTC or MEN 2, the current weight of clinical evidence does not indicate an elevated cancer risk for you.

Q: Does semaglutide cause pancreatic cancer? No causal link between semaglutide and pancreatic cancer has been established. While pancreatitis is a rare known adverse event, it has not translated into elevated pancreatic cancer rates in large human trials.

Q: Can GLP-1 drugs actually lower cancer risk? Early observational data suggests possible reductions in some obesity-related cancers, but this is associational evidence. Controlled trials specifically designed to test this question have not yet reported.

The Bottom Line

The cancer question around Ozempic deserves a straight answer: based on all available human clinical evidence — including more than 10,000 patients in the SUSTAIN programme and 17,604 patients in the SELECT trial — semaglutide has not been shown to increase cancer risk in humans.

The rodent data is real, which is why the black box warning exists and why the contraindications for MTC and MEN 2 are firm. But for the broader population considering semaglutide, the evidence does not support cancer as a reason to avoid it — assuming no other contraindications apply.

Medical decisions involving prescription medication should always involve a qualified healthcare provider who knows your individual history.

Ready to explore medically supervised weight management in Singapore? Noah's clinical team takes a thorough medical history — including any cancer risk factors — before prescribing. Start your consultation at ofnoah.sg

This article is for informational purposes only. It does not constitute medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.